» Articles » PMID: 30770366

ATM Inhibition Sensitizes Tumors to High-Dose Irradiation

Overview
Journal Cancer Res
Specialty Oncology
Date 2019 Feb 17
PMID 30770366
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Mechanistic studies of high-dose irradiation are important to improve our understanding on how the efficacy of stereotactically delivered high-dose irradiation can be enhanced by therapeutics such as ataxia-telangiesctasia-mutated (ATM) inhibitors. In this issue of , Torok and colleagues found that a single 15 Gy radiation dose eliminated lung tumor growth in mice when ATM was deleted in cancer cells versus when deleted in endothelial cells. These data support the establishment of clinical trials testing ATM inhibitors in combination with highly conformal radiotherapy or high-dose rate brachytherapy..

Citing Articles

DNA repair deficiency and the immune microenvironment: A pathways perspective.

Zhou Y, Mouw K DNA Repair (Amst). 2023; 133:103594.

PMID: 37980867 PMC: 10841828. DOI: 10.1016/j.dnarep.2023.103594.


Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Waqar S, Robinson C, Olszanski A, Spira A, Hackmaster M, Lucas L Invest New Drugs. 2022; 40(3):596-605.

PMID: 35150356 PMC: 9098584. DOI: 10.1007/s10637-022-01216-8.


ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.

Armstrong S, Schultz C, Azimi-Sadjadi A, Brody J, Pishvaian M Mol Cancer Ther. 2019; 18(11):1899-1908.

PMID: 31676541 PMC: 6830515. DOI: 10.1158/1535-7163.MCT-19-0208.